BioCryst Pharmaceuticals Inc. [BCRX] stock Downgrade by Barclays analyst, price target now $13


BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] slipped around -0.18 points on Thursday, while shares priced at $9.12 at the close of the session, down -1.94%. The company report on June 9, 2022 that BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in the pan-Latin America (LATAM) region.

“We are pleased to join forces with Pint Pharma to bring our oral, once-daily therapy to hereditary angioedema patients in LATAM who are in need of a new treatment option. Pint Pharma is the ideal partner for BioCryst based on the team’s deep experience in rare diseases that spans multiple aspects of commercialization and their established network across this important region,” said Charlie Gayer, chief commercial officer of BioCryst.

BioCryst Pharmaceuticals Inc. stock is now -34.15% down from its year-to-date (YTD) trading value. BCRX Stock saw the intraday high of $9.235 and lowest of $8.54 per share. The company’s 52-week high price is 19.99, which means current price is +19.84% above from all time high which was touched on 02/16/22.

Compared to the average trading volume of 4.72M shares, BCRX reached a trading volume of 4550499 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about BioCryst Pharmaceuticals Inc. [BCRX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $17.45 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barclays have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 18, 2022. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $21 to $14. The new note on the price target was released on April 11, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $16, while Oppenheimer analysts kept a Outperform rating on BCRX stock.

The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.62, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 9.58.

How has BCRX stock performed recently?

BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.06. With this latest performance, BCRX shares gained by 2.47% in over the last four-week period, additionally sinking by -23.17% over the last 6 months – not to mention a drop of -44.25% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 42.73, with the RSI for the last a single of trading hit 39.34, and the three-weeks RSI is set at 43.04 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 9.96, while it was recorded at 9.42 for the last single week of trading, and 13.54 for the last 200 days.

BioCryst Pharmaceuticals Inc. [BCRX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -113.08 and a Gross Margin at +94.88. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -117.11.

BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.30.

Earnings analysis for BioCryst Pharmaceuticals Inc. [BCRX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 15.20%.

Insider trade positions for BioCryst Pharmaceuticals Inc. [BCRX]

There are presently around $1,172 million, or 71.60% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 14,101,975, which is approximately -4.635% of the company’s market cap and around 1.10% of the total institutional ownership; VANGUARD GROUP INC, holding 13,207,040 shares of the stock with an approximate value of $120.45 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $115.92 million in BCRX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 117 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 26,889,301 shares. Additionally, 94 investors decreased positions by around 16,571,438 shares, while 46 investors held positions by with 85,068,223 shares. The mentioned changes placed institutional holdings at 128,528,962 shares, according to the latest SEC report filing. BCRX stock had 50 new institutional investments in for a total of 10,632,129 shares, while 24 institutional investors sold positions of 2,193,109 shares during the same period.